

1091101376

Abstract of the Disclosure

A method of predicting the lymphotropic metastatic potential of a solid non-lymphoid tumor. The percentage of cells of each of a plurality of representative samples of the tumor which express lymphoid gene products is determined. The metastatic potential is predicted to be low when no tumor cells in all of the samples are detected to express lymphoid gene products. The metastatic potential is predicted to be high when a high percentage of tumor cells in at least one of the samples are detected to express lymphoid gene products. A solid non-lymphoid tumor is treated by systemically administering a substance comprising a therapeutically effective amount of a molecule linked to a toxin, radionuclide, or chemotherapeutic agent and having binding specificity for a tumor specific lymphoid gene product idiotype. The lymphotropic metastatic potential of a primary solid non-lymphoid tumor is predicted by sub-cutaneously injecting cells from the tumor into at least one anti-AsGMI-treated nude mouse and examining the mouse for tumors at sites other than the site of injection.

001-0376-051376